Topic: acute myeloid leukemia (AML)

Xospata

52. Xospata

Xospata won an FDA nod to treat relapsed or refractory acute myeloid leukemia patients with a FLT3 mutation.
pfizer

49. Daurismo

Daurismo marked Pfizer's fourth FDA-approved NME oncology drug with in a two-month period.
Agios

20. Tibsovo

Tibsovo won't be a blockbuster with peak sales hovering around the $300 million mark, but it’s still on the hook to treat around 700 to 1,100 AML patients with the IDH1 mutation in the U.S.